EP3011036A1 - Transgenic plants - Google Patents
Transgenic plantsInfo
- Publication number
- EP3011036A1 EP3011036A1 EP14732858.7A EP14732858A EP3011036A1 EP 3011036 A1 EP3011036 A1 EP 3011036A1 EP 14732858 A EP14732858 A EP 14732858A EP 3011036 A1 EP3011036 A1 EP 3011036A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- seq
- plant
- sequence
- sequences
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
- C12N15/8251—Amino acid content, e.g. synthetic storage proteins, altering amino acid biosynthesis
- C12N15/8254—Tryptophan or lysine
Definitions
- the invention relates to methods for producing transgenic plants with improved phenotypic traits and relates methods and uses.
- lysine is an important nutritional component in the feeds of livestock, which in turn contribute an extensive portion of the lysine required by humans (Galili et al, WHO Technical Report).
- Such technology has the capacity to deliver crops or plants having various improved economic, agronomic or horticultural traits.
- Genetic engineering approaches have been successful in a limited number of crop plants, including soybean, rapeseed and maize. Mutant high-Lys lines have been obtained in maize opaque-2 mutants (Mertz et al) and opaqt/e-2-derived QPM lines (Geevers et al, Glover et al); whereas genetic engineering approaches have been used to increase the lysine content in maize (Frizzi et al, Houmard et al) and rice (Wu et al).
- RNA interference based on small interfering RNAs (siRNAs).
- siRNAs small interfering RNAs
- a (alpha), ⁇ (beta), ⁇ (gamma), and ⁇ (omega) gliadins of hard wheat and flour can be silenced by interference RNA (iRNA) through use of a polynucleotide that is transcribed into an hpRNA (hairpin RNA).
- iRNA interference RNA
- this polynucleotide whose expression is specifically directed in particular to tissues of wheat seeds through gene expression-regulating sequences such as, for example, the promoter of a gene of ⁇ gliadins or the promoter of the gene that codes for a D-hordein, one achieves post-transcriptional silencing of all of the genes of the species soft wheat and hard wheat in an effective and synergistic manner, as one is able to silence a greater number of gliadin genes compared to the results of silencing of a and ⁇ gliadins by hpRNA described in the prior art.
- gene expression-regulating sequences such as, for example, the promoter of a gene of ⁇ gliadins or the promoter of the gene that codes for a D-hordein
- RNAi is a technology based on the principle that small, specifically designed, chemically synthesized double-stranded RNA fragments can mediate specific messenger RNA (mRNA) degradation in the cytoplasm and hence selectively inhibit the synthesis of specific proteins.
- mRNA messenger RNA
- This technology has emerged as a very powerful tool to develop new compounds aimed at blocking and/or reducing anomalous activities in defined proteins.
- Compounds based on RNA interference can be rationally designed to block expression of any target gene, including genes for which traditional small molecule inhibitors cannot be found.
- RNAi has been shown to occur in mammalian cells, not only through long double- stranded RNA (dsRNA) but by means of double-stranded siRNAs.
- siRNAs are molecules of double-stranded RNA of 21 -25 nucleotides that originate from a longer precursor dsRNA.
- RNAi RNAi is initiated when dsRNAs are processed by an RNase Ill-like protein known as Dicer.
- Precursor dsRNAs may be of endogenous origin, in which case they are referred to as miRNAs (encoded in the genome of the organism) or of exogenous origin (such as viruses or transgenes).
- the protein Dicer typically contains an N-terminal RNA helicase domain, an RNA-binding so-called Piwi/Argonaute/Zwille (PAZ) domain, two RNase III domains and a double- stranded RNA binding domain (dsRBD) and its activity leads to the processing of the long double stranded RNAs into 21 -24 nucleotide double stranded siRNAs with 2 base 3' overhangs and a 5' phosphate and 3' hydroxyl group.
- PAZ Piwi/Argonaute/Zwille
- dsRBD double- stranded RNA binding domain
- thermodynamic characteristics of the 5' end of the siRNA determine which of the two strands is incorporated into the RISC complex.
- the strand that is less stable at the 5' end is normally incorporated as the guide strand, either because it has a higher content of AU bases or because of imperfect pairings.
- the guide strand must be complementary to the mRNA to be silenced in order for post-transcriptional silencing to occur.
- siRNA duplexes are then incorporated into the effector complex RISC, where the antisense or guide strand of the siRNA guides RISC to recognize and cleave target mRNA sequences upon adenosine-triphosphate (ATP)-dependent unwinding of the double-stranded siRNA molecule through an RNA helicase activity.
- RISC adenosine-triphosphate
- the catalytic activity of RISC which leads to mRNA degradation, is mediated by the endonuclease Argonaute 2 (AG02).
- AG02 belongs to the highly conserved Argonaute family of proteins. Argonaute proteins are -100 KDa highly basic proteins that contain two common domains, namely PIWI and PAZ domains.
- the PIWI domain is crucial for the interaction with Dicer and contains the nuclease activity responsible for the cleavage of mRNAs.
- AG02 uses one strand of the siRNA duplex as a guide to find messenger RNAs containing complementary sequences and cleaves the phosphodiester backbone between bases 10 and 1 1 relative to the guide strand's 5' end.
- An important step during the activation of RISC is the cleavage of the sense or passenger strand by AG02, removing this strand from the complex.
- siRNA effectors into the cells or tissues, where they will activate RISC and produce a potent and specific silencing of the targeted mRNA.
- the invention relates to a method for increasing lysine content in a plant, plant part or plant product derived therefrom comprising introducing and expressing a polynucleotide that is at least 80%, at least 90% or at least 95% identical to a sequence comprising two sequence pairs (a1 -a2) and (b2-b1 ) separated by a spacer sequence in which:
- sequences a1 , a2, b1 , and b2 are different sequences and are selected from SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, wherein
- a2 is SEQ ID NO: 2 or SEQ ID NO: 3, and
- a1 is SEQ ID NO: 2 or SEQ ID NO: 3
- b1 is SEQ I D NO: 3 or SEQ ID NO:
- the invention relates to a method for increasing lysine content in a food or feed composition
- a nucleic acid construct comprising a polynucleotide that is at least 80%, at least 90% or at least 95% identical to a sequence comprising two sequence pairs (a1 -a2) and (b2-b1 ) separated by a spacer sequence in which:
- sequences a1 , a2, b1 , and b2 are different sequences and are selected from SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, wherein
- a1 is SEQ ID NO: 1 or SEQ I D NO: 4
- b1 is SEQ I D NO: 4 or SEQ ID NO: 1
- a2 is SEQ ID NO: 2 or SEQ ID NO: 3
- a1 is SEQ I D NO: 2 or SEQ ID NO: 3
- b1 is SEQ ID NO: 3 or SEQ ID NO: 2
- a2 is SEQ ID NO: 1 or SEQ ID NO: 4 in a plant
- step b) obtaining a progeny plant derived from the plant of step a) and
- the invention relates to a use of a nucleic acid construct comprising a polynucleotide that is at least 80%, at least 90% or at least 95% identical to a sequence comprising two sequence pairs (a1 -a2) and (b2-b1 ) separated by a spacer sequence in which:
- sequences a1 , a2, b1 , and b2 are different sequences and are selected from SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO:4, wherein
- a1 is SEQ ID NO: 1 or SEQ I D NO: 4
- b1 is SEQ I D NO: 4 or SEQ ID NO: 1
- a2 is SEQ ID NO: 2 or SEQ ID NO: 3
- a1 is SEQ ID NO: 2 or SEQ ID NO: 3
- b1 is SEQ I D NO: 3 or SEQ I D NO: 2
- a2 is SEQ ID NO: 1 or SEQ ID NO: 4
- the invention in increasing lysine content in a plant, plant part thereof or plant product.
- the invention relates to a method for providing improved nutrition to a human or animal comprising feeding said human or animal on a diet comprising a food composition obtained by producing a plant or plant product with increased lysine content said method comprising
- sequences a1 , a2, b1 , and b2 are different sequences and are selected from SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, wherein
- a1 is SEQ ID NO: 1 or SEQ I D NO: 4
- b1 is SEQ I D NO: 4 or SEQ ID NO: 1
- a2 is SEQ ID NO: 2 or SEQ ID NO: 3
- c. if a1 is SEQ I D NO: 2 or SEQ ID NO: 3, b1 is SEQ ID NO: 3 or SEQ ID NO: 2, and a2 is SEQ ID NO: 1 or SEQ ID NO: 4
- the invention in another aspect, relates to a method for treating a condition associated with lysine deficiency comprising providing in the diet of a person or administering to a person or patient in need thereof an efficient amount of a food composition or food supplement obtained by producing a plant or plant product with increased lysine content said method comprising
- sequences a1 , a2, b1 , and b2 are different sequences and are selected from SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, wherein
- a1 is SEQ ID NO: 1 or SEQ I D NO: 4
- b1 is SEQ ID NO: 4 or SEQ I D NO: 1
- a2 is SEQ ID NO: 2 or SEQ ID NO: 3
- a1 is SEQ ID NO: 2 or SEQ ID NO: 3
- b1 is SEQ I D NO: 3 or SEQ I D NO: 2
- a2 is SEQ ID NO: 1 or SEQ ID NO: 4
- any of the methods described above may comprise the additional step of choosing a regenerated plant with an increased lysine content.
- the methods may comprise the additional steps of screening plants for those that comprise the polynucleotide construct above and which have an increased lysine content and selecting a plant that has an increased lysine content.
- steps or further steps include measuring the lysine content in said plant progeny, part thereof or product derived there from and optionally comparing the lysine content to that of a control plant, preferably a wild type plant.
- Harvesting lysine rich plant material, such as seeds, may also be included.
- the plant is wheat.
- FIG. 1 Shows the structure of the polynucleotide
- Figure A shows a polynucleotide that comprises the sequence pairs a1 -a2 and b2-b1 , separated by a spacer sequence (E) whose expression is directed by a gene expression-regulating sequence (R).
- E spacer sequence
- R gene expression-regulating sequence
- Figure B shows the hpRNA resulting from transcription of the polynucleotide represented in Figure A in which is formed a hairpin, in which the sequences Sec a1 , a2, b2, and b1 hybridize as is described. Subsequently, this RNA is processed, producing a new sequence of double-stranded RNA (dsRNA).
- dsRNA double-stranded RNA
- the final step shown refers to cleaving the sequence by enzymes such as, for example, the enzyme Dicer, such that double-stranded RNA sequences of approximately 21 -25 nucleotides, referred to as siRNA (small interfering RNA), are formed.
- FIG. 2 An example of the polynucleotide.
- sequence R is a promoter sequence of the gene of gamma-gliadin ( ⁇ gliadin) or D-hordein gene.
- Sequence E is a fragment of an intron of the maize ubiquitin gene.
- NOSt is a transcription termination sequence. This polynucleotide is inserted in this specific example into a pUC18 vector that has an ampicillin resistance gene.
- FIG. 3 Bread made from flour of transgenic plants and lysine content. Physical and organoleptic properties, and increased content of lysine.
- A Loaves and slices of wild-type BW208, transgenic line D793, and rice (as a control).
- B Physical properties of bread loaves obtained from wild-type lines, transgenic lines, and rice.
- C Descriptive sensory analysis. Lines with the same letter indicate that no significant differences exist among them as determined by the Tukey HSD post hoc all-pairwise comparison test (P ⁇ 0.05). Sensory scale ranges from 1 -9. In addition, most of the transgenic lines showed statistically comparable levels of quality in comparison with their wild type counterparts.
- FIG. 5 Comparative glutenin content
- nucleic acid As used herein, the words “nucleic acid”, “nucleic acid sequence”, “nucleotide”, “nucleic acid molecule” or “polynucleotide” are intended to include DNA molecules (e.g., cDNA or genomic DNA), RNA molecules (e.g., mRNA, siRNA, sRNA, dsRNA, miRNA), natural occurring, mutated, synthetic DNA or RNA molecules, and analogs of the DNA or RNA generated using nucleotide analogs. It can be single-stranded or double-stranded.
- nucleic acids or polynucleotides include, but are not limited to, coding sequences of structural genes, anti-sense sequences, and non-coding regulatory sequences that do not encode mRNAs or protein products. These terms also encompass a gene.
- the term "gene” or “gene sequence” is used broadly to refer to a DNA nucleic acid associated with a biological function. Thus, genes may include introns and exons as in the genomic sequence, or may comprise only a coding sequence as in cDNAs, and/or may include cDNAs, CDS or genomic DNA in combination with regulatory sequences.
- transgenic means with regard to, for example, a nucleic acid sequence, specifically an RNA nucleic acid sequence or molecule, an expression cassette, gene construct, or a vector comprising the nucleic acid sequence or an organism transformed with the nucleic acid sequences, expression cassettes or vectors according to the invention, all those constructions brought about by recombinant methods in which either
- genetic control sequence(s) which is operably linked with the nucleic acid sequence according to the invention, for example a promoter, or
- the natural genetic environment is understood as meaning the natural genomic or chromosomal locus in the original plant or the presence in a genomic library.
- the natural genetic environment of the nucleic acid sequence is preferably retained, at least in part.
- the environment flanks the nucleic acid sequence at least on one side and has a sequence length of at least 50 bp, preferably at least 500 bp, especially preferably at least 1000 bp, most preferably at least 5000 bp.
- a naturally occurring expression cassette for example the naturally occurring combination of the natural promoter of the nucleic acid sequences with the corresponding nucleic acid sequence encoding a polypeptide useful in the methods of the present invention, as defined above - becomes a transgenic expression cassette when this expression cassette is modified by non-natural, synthetic ("artificial") methods such as, for example, mutagenic treatment. Suitable methods are described, for example, in US 5,565,350 or WO 00/15815 both incorporated by reference.
- transgenic plant for the purposes of the invention is thus understood as meaning, as above, that the nucleic acids used in the method of the invention are not at their natural locus in the genome of said plant, it being possible for the nucleic acids to be expressed homologously or heterologously.
- transgenic preferably means that the nucleic acids is expressed homologously.
- transgenic also means that, while the nucleic acids according to the different embodiments of the invention are at their natural position in the genome of a plant, the sequence has been modified with regard to the natural sequence, and/or that the regulatory sequences of the natural sequences have been modified.
- Transgenic is preferably understood as meaning the expression of the nucleic acids according to the invention at an unnatural locus in the genome, i.e. homologous or, preferably, heterologous expression of the nucleic acids takes place.
- the transgene is integrated into the plant in a stable manner and the plant is preferably homozygous for the transgene.
- a "stably" transformed plant is a plant in which the exogenous DNA or RNA is heritable.
- the exogenous DNA or RNA may be heritable as a fragment of DNA maintained in the plant cell and not inserted into the host genome.
- the stably transformed plant comprises the exogenous DNA or RNA.
- progeny means any subsequent generation, including the seeds and plants therefrom, which is derived from a particular parental plant or set of parental plants; the resultant progeny may be hybridized or substantially homozygous, depending upon pedigree.
- Progeny of a transgenic plant of this present invention can be, for example, self-pollinated, crossed to another transgenic plant, crossed to a non-transgenic plant, and/or back crossed to an ancestor.
- siNAs of the invention refers to a double stranded oligonucleotide capable of mediating target mRNA cleavage via RNA interference.
- the aspects of the invention involve recombination DNA technology and in a preferred embodiment exclude embodiments that are solely based on generating plants by traditional breeding methods.
- the invention relates to a method for increasing lysine content in a plant, part thereof or plant product comprising
- sequences a1 , a2, b1 , and b2 are different sequences and are selected from SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4 wherein
- a2 is SEQ ID NO: 2 or SEQ ID NO: 3, and
- a1 is SEQ I D NO: 2 or SEQ I D NO: 3
- b1 is SEQ ID NO: 3 or SEQ ID NO:
- a2 is SEQ ID NO: 1 or SEQ ID NO: 4.
- the invention relates to the use of a polynucleotide that is at least 80%, at least 90% or at least 95% identical to a sequence comprising two sequence pairs (a1 -a2) and (b2-b1 ) separated by a spacer sequence in which:
- sequences a1 , a2, b1 , and b2 are different sequences and are selected from SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, wherein
- a2 is SEQ ID NO: 2 or SEQ ID NO: 3, and
- a1 is SEQ I D NO: 2 or SEQ I D NO: 3
- b1 is SEQ ID NO: 3 or SEQ ID NO:
- the use may include the step of transforming a plant with said polypeptide.
- a plant product according to the invention can be a food or feed composition obtained from the plant or part thereof expressing a polynucleotide as described herein.
- a food composition is for human consumption, is made using preferably plant seeds and is selected from, but not limited to, bread or other bakery products comprising flour, pasta, dumplings or cereal based drinks.
- the term food composition also includes vitamin supplements and nutritional supplements.
- a feed composition is a feed composition for animal consumption that is made using plants of parts thereof, preferably harvestable parts such as plant seeds.
- the invention therefore relates to a method for increasing lysine content in a food or feed composition
- a method for increasing lysine content in a food or feed composition comprising
- sequences a1 , a2, b1 , and b2 are different sequences and are selected from SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4 wherein
- a1 is SEQ I D NO: 1 or SEQ ID NO: 4
- b1 is SEQ ID NO: 4 or SEQ I D NO: 1
- a2 is SEQ ID NO: 2 or SEQ ID NO: 3
- a1 is SEQ I D NO: 2 or SEQ I D NO: 3
- b1 is SEQ ID NO: 3 or SEQ ID NO: 2
- a2 is SEQ ID NO: 1 or SEQ ID NO: 4.
- the composition is a feed composition. In one embodiment, the composition is a food composition.
- the method may further comprise the step of choosing a regenerated plant with increased lysine content. Optional additional steps are set out below.
- the method may further comprise the steps of
- lysine content is increased compared to a control plant, plant part thereof or control plant product.
- the control plant does not express the polynucleotide as described herein.
- a control plant as used herein is a plant, which has not been modified according to the methods of the invention. Accordingly, the control plant has not been genetically modified to express a nucleic acid as described herein.
- the control plant is preferably a wild type (WT) plant.
- WT wild type
- the control plant is a plant that does not carry a transgene according to the methods described herein, but expresses a different transgene.
- the control plant is typically of the same plant species, preferably the same variety or ecotype as the plant to be assessed.
- a control plant or plant cell may thus comprise, for example: (a) a wild-type plant or cell, i.e., of the same genotype as the starting material for the genetic alteration which resulted in the subject plant or cell; (b) a plant or plant cell of the same genotype as the starting material but which has been transformed with a null construct (i.e., with a construct which has no known effect on the trait of interest, such as a construct comprising a marker gene); (c) a plant or plant cell which is a non-transformed segregant among progeny of a subject plant or plant cell; (d) a plant or plant cell genetically identical to the subject plant or plant cell but which is not exposed to conditions or stimuli that would induce expression of the gene of interest or (e) the subject plant or plant cell itself, under conditions in which the gene of interest is not expressed.
- a wild-type plant or cell i.e., of the same genotype as the starting material for the genetic alteration which resulted in the subject plant or cell
- the method for increasing lysine content in a plant, part thereof or plant product described above further comprises the step of choosing a regenerated plant with increased lysine content. It may also comprise the additional steps of obtaining a progeny plant, that is a regenerated plant, derived from said plant and selecting a lysine enriched part of said plant. Selecting a lysine enriched part can be carried out by assessing lysine content in said plant and comparing lysine content to a wild type plant.
- the lysine enriched part is, in one embodiment, seeds.
- the method may also comprise the step of harvesting the lysine rich part.
- the method may also optionally comprise the steps of screening plants for those that comprise the polynucleotide construct above and which have an increased lysine content and selecting or choosing a plant that has an increased lysine content.
- further steps include measuring the lysine content in said plant progeny, part thereof or product derived therefrom and comparing the lysine content to that of a control plant.
- the progeny plant is stably transformed and comprises the exogenous polynucleotide which is heritable as a fragment of DNA maintained in the plant cell and the method may include steps to verify that the construct is stably integrated.
- the method may also comprise the additional step of collecting seeds from the selected progeny plant and producing a food or feed composition.
- the invention relates to a method for increasing lysine content in a plant, plant part or plant product derived therefrom comprising a) introducing and expressing a polynucleotide that is at least 80%, at least 90%, at least 95% identical to a sequence comprising two sequence pairs (a1 -a2) and (b2-b1 ) separated by a spacer sequence in which:
- sequences a1 , a2, b1 , and b2 are different sequences and are selected from SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, wherein b. if a1 is SEQ ID NO: 1 or SEQ I D NO: 4, b1 is SEQ I D NO: 4 or SEQ ID NO:
- a2 is SEQ ID NO: 2 or SEQ ID NO: 3, and
- a1 is SEQ I D NO: 2 or SEQ I D NO: 3
- b1 is SEQ ID NO: 3 or SEQ ID NO:
- a2 is SEQ ID NO: 1 or SEQ ID NO: 4;
- Selecting a lysine enriched part can be carried out by comparing lysine content to a wild type plant.
- the lysine enriched part is, in one embodiment, seeds.
- the method may also comprise the step of harvesting the lysine rich part.
- the method may also optionally comprise the steps of screening plants for those that comprise the polynucleotide construct above and which have increased lysine content and selecting a plant that has an increased lysine content.
- further steps include measuring the lysine content in said plant progeny, part thereof or product derived therefrom and comparing the lysine content to that of a control plant.
- the method may also comprise the additional step of producing a food or feed composition.
- the invention relates to a method for increasing lysine content in a plant, plant part or plant product derived therefrom comprising a) introducing and expressing a polynucleotide that is at least 80%, at least 90%, at least 95% identical to a sequence comprising two sequence pairs (a1 -a2) and (b2-b1 ) separated by a spacer sequence in which:
- sequences a1 , a2, b1 , and b2 are different sequences and are selected from SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, wherein b. if a1 is SEQ ID NO: 1 or SEQ I D NO: 4, b1 is SEQ I D NO: 4 or SEQ ID NO:
- a2 is SEQ ID NO: 2 or SEQ ID NO: 3, and
- a1 is SEQ I D NO: 2 or SEQ I D NO: 3
- b1 is SEQ ID NO: 3 or SEQ ID NO:
- a2 is SEQ ID NO: 1 or SEQ ID NO: 4;
- the method may also comprise the additional step of producing a food or feed composition. This is rich in lysine compared to a control plant or part thereof or food or feed composition.
- lysine content is increased in plant seeds or grain, for example wheat grain.
- products derived from a plant expressing a polynucleotide as above can be processed in the same way as control plants.
- a transgenic seed of the present invention with increased lysine is especially useful as a feed or food product, a source of purified plant protein products, or a source of other products processed from the seed that contain a higher lysine content than a control plant or part thereof of a similar variety.
- seed obtained have a sufficient quantity of lysine such that the livestock feed or food product made from the grain does not require supplementation from additional lysine sources.
- the high lysine seed described herein achieves this level of lysine production and accumulation.
- non-gluten proteins rich in lysine are upregulated in the transgenic plants. Therefore, the methods described herein can also be used to upregulate non-gluten proteins compared to a control plant.
- the invention also relates to a method for upregulate non-gluten protein content in a plant, plant part or plant product derived therefrom comprising introducing and expressing a polynucleotide that is at least 80%, at least 90% or at least 95% identical to a sequence comprising two sequence pairs (a1 -a2) and (b2-b1 ) separated by a spacer sequence in which:
- sequences a1 , a2, b1 , and b2 are different sequences and are selected from SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, wherein b. if a1 is SEQ ID NO: 1 or SEQ I D NO: 4, b1 is SEQ I D NO: 4 or SEQ ID NO:
- a2 is SEQ ID NO: 2 or SEQ ID NO: 3, and
- a1 is SEQ I D NO: 2 or SEQ I D NO: 3
- b1 is SEQ ID NO: 3 or SEQ ID NO:
- a2 is SEQ ID NO: 1 or SEQ ID NO: 4.
- lysine content refers to total lysine content. According to the various aspects of the invention, lysine content can be measured using standard methods described in the art and as shown in the examples. It can be measured as part of the total amino acid content in proteins and/or as the free amino acid content following protein hydrolysis. In one embodiment, it is measured following protein hydrolysis and lysine that forms part of proteins as well as free lysine is thus measured.
- the lysine content is measured in a plant product, for example flour, such as wholemeal flour, obtained from grain of transgenic plants expressing the polynucleotide according to the methods described herein.
- a plant product for example flour, such as wholemeal flour, obtained from grain of transgenic plants expressing the polynucleotide according to the methods described herein.
- the amino acids are the analysed using chromatographic separation of the amino acids present in the test sample using by column technique.
- chromatographic separation uses post-column derivatization in that the amino acids are separated by means of ion exchange, and derivatives are formed after they have emerged from the column so that they may be quantified.
- Ion-exchange chromatography uses post-column derivatization in that the amino acids are separated by means of ion exchange, and derivatives are formed after they have emerged from the column so that they may be quantified.
- the most common derivatization procedure is that using ninhydrin with subsequent determination of optical density.
- pre-column derivatization as is used for gas-liquid chromatography (GLC) and high-performance liquid chromatography (HPLC), uses columns to separate the amino acid derivatives. These derivatives, after emerging from the column, are then quantified by various detection devices.
- HPLC High-Performance Liquid Chromatography
- pre-column derivatization is required for amino acid analysis.
- Dansyl chloride (5-dimethylamino-1 -naphthalene sulphonyl chloride) is frequently used for this purpose, producing fluorescent dansyl derivatives that are separated by a reversed phase column chromatographic procedure.
- the column employs silica gel with attached non-polar hydrocarbon functional groups (e.g., octadecyl moieties) as the stationary phase and uses a multi- step non-linear elusion procedure.
- non-polar hydrocarbon functional groups e.g., octadecyl moieties
- acetonitrile and water mixtures have been suggested for the separation of dansylated amino acids. These are then detected and measured by a fluorescence detector, which can provide detection limits in the picogram range.
- Ion-Exchange Chromatography lon- exchange chromatography can be used in amino acid analysis. In this method, lithium or sodium buffers, narrow columns with fine spherical resin particles, and fluorescamine or ninhydrin, are used.
- lysine content in the plant or part thereof, for example in the seed, or in a plant product, for example flour or bread is increased or enhanced by about 10% to about 80% compared to the control (preferably wild type), preferably about 20% to about 70%, for example 20%, 25%, 30%, 35% 40% or 45%, more preferably about 24% to about 67%
- the lysine content in flour obtained from a wild type plant is about 0.57% to about 0.70% (% w/w), depending on the cultivar used.
- the lysine content in flour obtained from a transgenic plant is more than about 0.7%, for example more than about 0.7% to about 0.98%, for example 0.7%, 0.75%, 0.8%, 0.85%, 0.9%, 0.95% (% w/w).
- a lysine rich plant or part thereof as described herein has increased lysine content as defined above.
- the sequences a1 -a2 and b2-b1 in the polypeptide used in the various aspects of the invention described herein are linked to form a linear and continuous nucleotide sequence in which the two pairs are linked by a spacer sequence.
- the spacer sequence is a non-coding sequence that is eliminated after the process of forming dsRNA.
- the spacer sequence may be part of a sequence of an intron of a gene.
- the function of the spacer sequence is to act as a hinge for the sequence pairs described so that pairing or hybridization of the RNA sequences coding for the polynucleotide may take place.
- the polynucleotide used in the various aspects of the invention described herein is a polynucleotide that comprises two sequence pairs (a1 -a2) and (b2-b1 ) separated by a spacer sequence in which the sequences a1 , a2, b1 , and b2 are described above.
- the sequences a1 -a2 and b2-b1 (referred to in the following as the sequence pairs of the invention) are linked to form a linear and continuous nucleotide sequence in which, in turn, the two pairs are linked by means of a spacer sequence at least one nucleotide in length.
- the polynucleotide comprises sequences a1 -a2 and b2-b1 which are selected from SEQ ID NO: 1 , 2, 3 and 4 as shown in tables 1 and 2 is at least 80%, preferably at least 90%, preferably at least 95% identical with the polynucleotide comprising sequences a1 -a2 and b2-b1 selected from SEQ ID NO: 1 , 2, 3 and 4 as shown in Tables 1 and 2.
- Sequence identity is, for example, at least 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.
- sequence identity is 100%.
- the polynucleotide comprises sequences a1 , a2, b1 , and b2 which are all different sequences, that is they all differ from each other, and are selected from SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4 respectively or sequences with at least 90% homology to one or more of these sequences.
- sequence identity is at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.
- a1 consists of or comprises SEQ ID NO:1 or a sequence with at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto
- a2 consists of or comprises SEQ ID NO:2 or a sequence with at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto
- b1 consists of or comprises SEQ ID NO:3 or a sequence with at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto
- b2 consists of or comprises SEQ ID NO:4 or a sequence with at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto.
- sequences a1 , a2, b1 , and b2 are all different sequences and are selected from SEQ ID NO: 1 , SEQ I D NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4.
- a1 consists of or comprises SEQ ID NO: 1
- a2 consists of or comprises SEQ ID NO:2
- b1 consists of or comprises SEQ ID NO:3
- b2 consists of or comprises SEQ ID NO:4.
- SEQ ID NO: 1 is a sense sequence that comprises a part of the fragment that codes for the epitopes of ⁇ gliadins recognized by human T cells that give rise to an immune response in persons suffering from celiac disease.
- SEQ ID NO: 2 is the sense sequence that comprises a part of the fragment that codes for the epitopes of ⁇ , ⁇ , and Y gliadins.
- SEQ ID NO: 3 is the antisense sequence of SEQ ID NO: 2
- SEQ ID NO: 4 is the antisense sequence of SEQ ID NO: 1.
- the polynucleotide used in the various aspects of the invention gives rise to RNA in which the two sequence pairs hybridize thus forming a hairpin.
- the polynucleotide used according to the various aspects of the invention covers various combinations of sequences through which RNA hairpins can be obtained are shown in Table 1 and Table 2. Any of these combinations can be used according to the various embodiments of the invention.
- the RNA sequence coded for by the polynucleotide described herein is capable of forming an hpRNA in which the sequence coded for by the pair a1 -a2 completely hybridizes with the sequence coded for by the pair b2-b1 .
- An hpRNA is a hairpin shape formed by hybridization of the transcribed sequences.
- the polynucleotide in the various aspects was used as a template for synthesizing the transcribed sequences, as can be seen in Figure 1 B.
- hpRNA is a double-stranded RNA (dsRNA) that is cleaved by an endoribonuclease, for example the endoribonuclease Dicer, resulting in fragments of approximately 21 -25 nts. These fragments are known as siRNA. As has been described above, the siRNAs cause post- transcriptional silencing of the target nucleotide sequences so that no protein is obtained.
- dsRNA double-stranded RNA
- the polynucleotide according the aspects of the invention is at least one siRNA generated from the sequence of the hpRNA according to the previous aspect.
- the siRNA can also be referred to as RNAi.
- the siRNA is a double-stranded RNA of between 21 and 25 nucleotides, but is not limited to this number of nucleotides, and it is generated from the hpRNA sequence of the invention.
- the approximate number of nucleotides of the siRNA it is understood that there is another strand that is complementary to this sequence, i.e., that one can use the terms nucleotides or base pairs (bp) interchangeably.
- the Dicer enzyme cleaves the dsRNA into double-stranded fragments of approximately 21 -25 nucleotides (siRNA), with the 5' end phosphorylated and two unpaired nucleotides protruding at the 3' end.
- siRNA double-stranded fragments of approximately 21 -25 nucleotides
- the guide strand Of the two strands of siRNA, only one, referred to as the guide strand, is incorporated into the enzymatic complex RISC, while the other is degraded.
- the thermodynamic characteristics of the 5' end of the siRNA determine which of the two strands is incorporated into the RISC complex. The strand that is less stable at the 5' end is normally incorporated as the guide strand.
- the guide strand must be complementary to the mRNA that is to be silenced in order for post-transcriptional silencing to occur. Subsequently, the RISC complex binds to the complementary mRNA of the guide strand of the siRNA present in the complex, and cleavage of the mRNA occurs.
- the polynucleotide may be an RNA sequence coded for by any of the polynucleotides above and capable of forming an hpRNA in which the sequence coded for by the pair a1 -a2 hybridizes completely with the sequence coded for by the pair b2-b1 .
- the polynucleotide may be an siRNA generated from the sequence of the hpRNA.
- sequences for the polynucleotide according to the aspects of the invention are sense or antisense sequences.
- the sequences may be selected from SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4.
- the sequences may be selected from sequences with at least 80%, 90% or at least 95% homology to SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, and/or SEQ ID NO: 4
- the combination of sequence pairs is combination 1 as shown above. In one embodiment, the combination of sequence pairs is combination 2 as shown above. In one embodiment, the combination of sequence pairs is combination 3 as shown above. In one embodiment according to the various aspects of the invention, the combination of sequence pairs is combination 4 as shown above. Table 2. Combinations of sequences for the polynucleotide according to the aspects of the invention in which the a1 -a2 and b2-b1 pairs contain sense and antisense sequences. The sequences may be selected from SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4. In another embodiment, the sequences may be selected from sequences with at least 80%, 90% or 95% homology to SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, and/or SEQ ID NO: 4
- the combination of sequence pairs is combination 1 as shown above. In one embodiment, the combination of sequence pairs is combination 2 as shown above. In one embodiment, the combination of sequence pairs is combination 3 as shown above. In one embodiment, the combination of sequence pairs is combination 4 as shown above.
- the polynucleotide comprises two sequence pairs (a1 -a2) and (b2-b1 ) separated by a spacer sequence in which a1 is SEQ ID NO: 1 , a2 is SEQ ID NO: 2, b2 is SEQ ID NO: 3, and b1 is SEQ ID NO: 4.
- SEQ ID NO: 2 This is the sense sequence of alpha, beta, gamma gliadins.
- the polynucleotide used in the various aspects of the invention confers, when expressed in a plant post-transcriptional silencing of all of the mRNAs (messenger RNA) that code for all types of wheat gliadins ( ⁇ , ⁇ , ⁇ , and ⁇ gliadins) and increases lysine content in the plant.
- mRNAs messenger RNA
- ⁇ , ⁇ , ⁇ , and ⁇ gliadins increases lysine content in the plant.
- the invention also relates to plants with reduced gliadin/gluten content and increased lysine content.
- the invention also relates to methods as described above which comprises silencing ⁇ , ⁇ , ⁇ , and ⁇ gliadins.
- the invention also relates to a method for silencing ⁇ , ⁇ , ⁇ , and ⁇ gliadins and increasing lysine content in a plant, plant part or plant product derived therefrom comprising introducing and expressing a polynucleotide that is at least 80%, at least 90% or at least 95% identical to a sequence comprising two sequence pairs (a1 -a2) and (b2-b1 ) separated by a spacer sequence in which:
- sequences a1 , a2, b1 , and b2 are different sequences and are selected from SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, wherein b. if a1 is SEQ ID NO: 1 or SEQ I D NO: 4, b1 is SEQ I D NO: 4 or SEQ ID NO:
- a2 is SEQ ID NO: 2 or SEQ ID NO: 3, and
- a1 is SEQ I D NO: 2 or SEQ I D NO: 3
- b1 is SEQ ID NO: 3 or SEQ ID NO:
- a2 is SEQ ID NO: 1 or SEQ ID NO: 4.
- the invention relates to a use of a nucleic acid construct comprising a polynucleotide that is at least 80%, at least 90% or at least 95% identical to a sequence comprising two sequence pairs (a1 -a2) and (b2-b1 ) separated by a spacer sequence in which:
- sequences a1 , a2, b1 , and b2 are different sequences and are selected from SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO:4, wherein
- a1 is SEQ ID NO: 1 or SEQ ID NO: 4
- b1 is SEQ ID NO: 4 or SEQ I D NO: 1
- a2 is SEQ ID NO: 2 or SEQ ID NO: 3
- a1 is SEQ ID NO: 2 or SEQ ID NO: 3
- b1 is SEQ I D NO: 3 or SEQ I D NO: 2
- a2 is SEQ ID NO: 1 or SEQ ID NO: 4
- the invention relates to a method for increasing lysine content and silencing ⁇ , ⁇ , ⁇ , and ⁇ gliadins in a food or feed composition comprising
- nucleic acid construct comprising a polynucleotide that is at least 80%, at least 90% or at least 95% identical to a sequence comprising two sequence pairs (a1 -a2) and (b2-b1 ) separated by a spacer sequence in which:
- sequences a1 , a2, b1 , and b2 are different sequences and are selected from SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, wherein
- a1 is SEQ ID NO: 1 or SEQ I D NO: 4
- b1 is SEQ ID NO: 4 or SEQ I D NO: 1
- a2 is SEQ ID NO: 2 or SEQ ID NO: 3
- a1 is SEQ ID NO: 2 or SEQ ID NO: 3
- b1 is SEQ I D NO: 3 or SEQ I D NO: 2
- a2 is SEQ ID NO: 1 or SEQ ID NO: 4 in a plant
- step b) obtaining a progeny plant derived from the plant of step a) and
- the invention in another aspect, relates to a method for treating a patient suffering from a condition associated with lysine deficiency and from coeliac disease comprising providing in the diet of a person or administering or a person in need thereof an effective amount of a food composition or food supplement obtained by producing a plant or plant product with increased lysine content and reduced gluten content said method comprising
- sequences a1 , a2, b1 , and b2 are different sequences and are selected from SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, wherein
- a1 is SEQ ID NO: 1 or SEQ I D NO: 4
- b1 is SEQ I D NO: 4 or SEQ ID NO: 1
- a2 is SEQ ID NO: 2 or SEQ ID NO: 3
- a1 is SEQ ID NO: 2 or SEQ I D NO: 3
- b1 is SEQ ID NO: 3 or SEQ ID NO: 2
- a2 is SEQ ID NO: 1 or SEQ ID NO: 4
- the polynucleotide comprises two sequence pairs (a1 -a2) and (b2-b1 ) separated by a spacer sequence in which a1 is SEQ ID NO: 1 , a2 is SEQ ID NO: 2, b2 is SEQ ID NO: 3, and b1 is SEQ ID NO: 4.
- the spacer sequence may be any suitable sequence and can be designed using methods in the art.
- the spacer is at least 10 nucleotides long.
- the polynucleotide comprises two sequence pairs (a1 -a2) and (b2-b1 ) as described herein in which the spacer sequence is SEQ ID NO: 5.
- the sequence SEQ ID NO: 5 is a fragment of an intron of the gene Ubi1 that codes for maize ubiquitin.
- Other suitable spacer sequences are known to the skilled person.
- the spacer sequence is a non-coding sequence that is eliminated after the process of forming dsRNA.
- the function of the spacer sequence is to act as a hinge for the sequence pairs described so that pairing or hybridization of the RNA sequences coding for the polynucleotide may take place.
- the polynucleotide described herein may be comprised in a vector such as an expression vector.
- vector refers to a DNA fragment that has the capacity to replicate itself in a particular host, and, as the term indicates, may serve as a vehicle for multiplying another DNA fragment that has been fused to it (an insert).
- Insert refers to a DNA fragment that is fused to the vector; in the case of the present invention, the vector comprises the polynucleotide of the invention, which, when fused thereto, can replicate itself in the corresponding host.
- Vectors may be plasmids, cosmids, bacteriophages, or viral vectors, without excluding other types of vectors that meet the present definition of vector.
- plant as used herein encompasses whole plants, ancestors and progeny of the plants and plant parts, including seeds, fruit, shoots, stems, leaves, roots (including tubers), flowers, and tissues and organs, wherein each of the aforementioned comprise the gene/nucleic acid of interest.
- plant also encompasses plant cells, suspension cultures, callus tissue, embryos, meristematic regions, gametophytes, sporophytes, pollen and microspores, again wherein each of the aforementioned comprises the gene/nucleic acid of interest.
- the various aspects of the invention described herein clearly extend to any plant cell or any plant produced, obtained or obtainable by any of the methods described herein, and to all plant parts and propagules thereof unless otherwise specified.
- the present invention extends further to encompass the progeny of a primary transformed or transfected cell, tissue, organ or whole plant that has been produced by any of the aforementioned methods, the only requirement being that progeny exhibit the same genotypic and/or phenotypic characteristic(s) as those produced by the parent in the methods according to the invention.
- the various aspects of the invention also extend to harvestable parts of a plant of the invention as described above such as, but not limited to seeds, leaves, fruits, flowers, stems, roots, rhizomes, tubers and bulbs.
- a part of a plant as used according to various aspects of the invention described herein preferably refers to seeds or grain, for example wheat grain.
- a plant product is derived from a harvestable part of such a plant, such as dry pellets or powders, flour, oil, fat and fatty acids, starch or proteins.
- the plant product is flour or semolina.
- the term "flour” as it is understood in the present invention refers to the product obtained by milling of any seed or plants of the genus Triticum, with the bran or husk of the seed removed to a greater or lesser degree.
- the term “semolina” refers to coarse flour (slightly milled wheat seeds), i.e., fragments of the endosperm with a variable amount of seed husks.
- the plant may be a monocot or dicot plant.
- the plant is a monocot crop plant.
- the plant is wheat and belongs to the genus Triticum.
- the invention therefore relates to a method for increasing lysine content in a plant of the genus Triticum, part thereof or a product derived therefrom comprising
- sequences a1 , a2, b1 , and b2 are different sequences and are selected from SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4 wherein
- a1 is SEQ ID NO: 1 or SEQ ID NO: 4
- b1 is SEQ ID NO: 4 or SEQ I D NO: 1
- a2 is SEQ ID NO: 2 or SEQ ID NO: 3
- a1 is SEQ I D NO: 2 or SEQ I D NO: 3
- b1 is SEQ ID NO: 3 or SEQ ID NO: 2
- a2 is SEQ ID NO: 1 or SEQ ID NO: 4
- Step b can be carried out by measuring the lysine content in said plant progeny, plant part or plant product derived therefrom and comparing the lysine content to that of a control plant.
- the invention relates to the use of a polynucleotide that is at least 80% identical to a sequence comprising two sequence pairs (a1 -a2) and (b2-b1 ) separated by a spacer sequence in which: a. the sequences a1 , a2, b1 , and b2 are different sequences and are selected from SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, wherein
- a2 is SEQ ID NO: 2 or SEQ ID NO: 3, and
- a1 is SEQ ID NO: 2 or SEQ I D NO: 3
- b1 is SEQ I D NO: 3 or SEQ ID NO:
- the plant part is preferably wheat (grain) and the product is preferably flour or bread.
- the plant is selected from the list that includes, but is not limited to, Triticum aestivum, T aethiopicum, T araraticum, T boeoticum, T carthlicum, T compactum, T dicoccoides, T dicoccum, T durum, T ispahanicum, T karamyschevii, T macha, T militinae, T monococcum, T polonicum, T repens, T spelta, T sphaerococcum, T timopheevii, T. turanicum, T turgidum, T urartu, T vavilovii and T zhukovskyi.
- the plant is of the species Triticum aestivum or Triticum turgidum.
- the plant belongs to the cultivar Bobwhite or the cultivar Don Pedro. More preferably, the cultivars BW208 and BW2003 (Bobwhite), which belong to the wheat species Triticum aestivum L. ssp aestivum, and the variety Don Pedro, which belongs to the wheat species Triticum turgidum L. ssp durum, are selected.
- the polynucleotide used in the various aspects of the invention comprises a regulatory element operably linked to its 5' end.
- regulatory element is used interchangeably herein with “control sequence” and “promoter” and all terms are to be taken in a broad context to refer to regulatory nucleic acid sequences capable of effecting expression of the sequences to which they are ligated.
- promoter typically refers to a nucleic acid control sequence located upstream from the transcriptional start of a gene and which is involved in recognising and binding of RNA polymerase and other proteins, thereby directing transcription of an operably linked nucleic acid.
- transcriptional regulatory sequences derived from a classical eukaryotic genomic gene (including the TATA box which is required for accurate transcription initiation, with or without a CCAAT box sequence) and additional regulatory elements (i.e. upstream activating sequences, enhancers and silencers) which alter gene expression in response to developmental and/or external stimuli, or in a tissue- specific manner.
- additional regulatory elements i.e. upstream activating sequences, enhancers and silencers
- a transcriptional regulatory sequence of a classical prokaryotic gene in which case it may include a -35 box sequence and/or -10 box transcriptional regulatory sequences.
- regulatory element also encompasses a synthetic fusion molecule or derivative that confers, activates or enhances expression of a nucleic acid molecule in a cell, tissue or organ.
- a “plant promoter” comprises regulatory elements, which mediate the expression of a coding sequence segment in plant cells. Accordingly, a plant promoter need not be of plant origin, but may originate from viruses or micro-organisms, for example from viruses which attack plant cells. The "plant promoter” can also originate from a plant cell, e.g. from the plant which is transformed with the nucleic acid sequence to be expressed in the inventive process and described herein. This also applies to other “plant” regulatory signals, such as "plant” terminators.
- the promoters upstream of the nucleotide sequences useful in the methods of the present invention can be modified by one or more nucleotide substitution(s), insertion(s) and/or deletion(s) without interfering with the functionality or activity of either the promoters, the open reading frame (ORF) or the 3'-regulatory region such as terminators or other 3' regulatory regions which are located away from the ORF. It is furthermore possible that the activity of the promoters is increased by modification of their sequence, or that they are replaced completely by more active promoters, even promoters from heterologous organisms.
- the nucleic acid molecule For expression in plants, the nucleic acid molecule must, as described above, be linked operably to or comprise a suitable promoter which expresses the gene at the right point in time and with the required spatial expression pattern.
- the promoter strength and/or expression pattern of a candidate promoter may be analysed for example by operably linking the promoter to a reporter gene and assaying the expression level and pattern of the reporter gene in various tissues of the plant.
- Suitable well-known reporter genes are known to the skilled person and include for example beta-glucuronidase or beta- galactosidase.
- the term "operably linked” as used herein refers to a functional linkage between the promoter sequence and the gene of interest, such that the promoter sequence is able to initiate transcription of the gene of interest.
- the nucleic acid sequence may be expressed using a promoter that drives overexpression.
- Overexpression means that the transgene is expressed at a level that is higher than expression of endogenous counterparts driven by their endogenous promoters.
- overexpression may be carried out using a strong promoter, such as a constitutive promoter.
- a "constitutive promoter” refers to a promoter that is transcriptionally active during most, but not necessarily all, phases of growth and development and under most environmental conditions, in at least one cell, tissue or organ.
- constitutive promoters examples include the cauliflower mosaic virus promoter (CaMV35S or 19S), rice actin promoter, maize ubiquitin promoter, rubisco small subunit, maize or alfalfa H3 histone, OCS, SAD1 or 2, GOS2 or any promoter that gives enhanced expression.
- CaMV35S or 19S cauliflower mosaic virus promoter
- rice actin promoter examples include the cauliflower mosaic virus promoter (CaMV35S or 19S), rice actin promoter, maize ubiquitin promoter, rubisco small subunit, maize or alfalfa H3 histone, OCS, SAD1 or 2, GOS2 or any promoter that gives enhanced expression.
- enhanced or increased expression can be achieved by using transcription or translation enhancers or activators and may incorporate enhancers into the gene to further increase expression.
- an inducible expression system may be used, where expression is driven by a promoter induced by environmental stress conditions (for example the pepper pathogen-induced membrane protein gene CaPIMPI or promoters that comprise the dehydration-responsive element (DRE), the promoter of the sunflower HD-Zip protein gene Hahb4, which is inducible by water stress, high salt concentrations and ABA or a chemically inducible promoter (such as steroid- or ethanol-inducible promoter system).
- the promoter may also be tissue-specific.
- the types of promoters listed above are described in the art. Other suitable promoters and inducible systems are also known to the skilled person.
- tissue-specific promoter preferably a seed specific promoter
- This is a promoter that is transcriptionally active predominantly in plant seeds, substantially to the exclusion of any other parts of a plant, whilst still allowing for any leaky expression in these other plant parts.
- seed specific promoters are those that regulate the expression of genes encoding seed storage proteins (e.g zein from maize (Zea mays L), phaseolin from kidney bean (Phaseolus vulgaris L.) or napin from Brassica), seed coat proteins or acyl carrier protein are joined to other than the homologous gene and introduced into a plant cell host for integration into the genome to provide for seed- specific transcription.
- seed storage proteins e.g zein from maize (Zea mays L), phaseolin from kidney bean (Phaseolus vulgaris L.) or napin from Brassica
- seed coat proteins or acyl carrier protein are joined to other than the homologous gene and introduced into a plant cell host for integration into the genome to provide for seed- specific transcription.
- the gene expression-regulating sequence is SEQ ID NO: 6 and/or SEQ ID NO: 7.
- the sequence SEQ ID NO: 6 corresponds to the sequence of a promoter of the ⁇ gliadin gene that shows a duplication in a proline box.
- SEQ I D NO: 7 corresponds to the sequence of a promoter of the D-hordein gene (the second nucleotide of this gene has the accession number AY998009 and belongs to the species Hordeum chilense). Both promoters are expressed in the endosperm of the seeds.
- the promoter is a constitutive or strong promoter.
- the regulatory sequence is an inducible promoter, a stress inducible promoter or a tissue specific promoter.
- the stress inducible promoter is selected from the following non limiting list: the HaHB1 promoter, RD29A (which drives drought inducible expression of DREB1A), the maize rabl7 drought-inducible promoter, P5CS1 (which drives drought inducible expression of the proline biosynthetic enzyme P5CS1 ), ABA- and drought-inducible promoters of Arabidopsis clade A PP2Cs (ABM , ABI2, HAB1 , PP2CA, HAM , HAI2 and HAI3) or their corresponding crop orthologs.
- the nucleic acid sequence is introduced into said plant through a process called transformation.
- transformation or transformation as referred to herein encompasses the transfer of an exogenous polynucleotide into a host cell, irrespective of the method used for transfer.
- Plant tissue capable of subsequent clonal propagation, whether by organogenesis or embryogenesis, may be transformed with a genetic construct of the present invention and a whole plant regenerated there from. The particular tissue chosen will vary depending on the clonal propagation systems available for, and best suited to, the particular species being transformed.
- tissue targets include leaf disks, pollen, embryos, cotyledons, hypocotyls, megagametophytes, callus tissue, existing meristematic tissue (e.g., apical meristem, axillary buds, and root meristems), and induced meristem tissue (e.g., cotyledon meristem and hypocotyl meristem).
- the polynucleotide may be transiently or stably introduced into a host cell and may be maintained non-integrated, for example, as a plasmid. Alternatively, it may be integrated into the host genome.
- the resulting transformed plant cell may then be used to regenerate a transformed plant in a manner known to persons skilled in the art.
- Transformation of plants is now a routine technique in many species.
- any of several transformation methods may be used to introduce the gene of interest into a suitable ancestor cell.
- the methods described for the transformation and regeneration of plants from plant tissues or plant cells may be utilized for transient or for stable transformation. Transformation methods include the use of liposomes, electroporation, chemicals that increase free DNA uptake, injection of the DNA directly into the plant, particle gun bombardment, transformation using viruses or pollen and microprojection. Methods may be selected from the calcium/polyethylene glycol method for protoplasts, electroporation of protoplasts, microinjection into plant material, DNA or RNA-coated particle bombardment, infection with (non-integrative) viruses and the like.
- Transgenic plants including transgenic crop plants, are preferably produced via Agrobacterium tumefaciens mediated transformation.
- the nucleic acid is preferably stably integrated in the transgenic plants genome and the progeny of said plant therefore also comprises the transgene.
- the plant material obtained in the transformation is, in certain embodiments, subjected to selective conditions so that transformed plants can be distinguished from untransformed plants.
- the seeds obtained in the above-described manner can be planted and, after an initial growing period, subjected to a suitable selection by spraying.
- a further possibility is growing the seeds, if appropriate after sterilization, on agar plates using a suitable selection agent so that only the transformed seeds can grow into plants.
- the transformed plants are screened for the presence of a selectable marker such as the ones described above.
- putatively transformed plants may also be evaluated, for instance using Southern analysis, for the presence of the gene of interest, copy number and/or genomic organisation. Alternatively or additionally, expression levels of the newly introduced nucleic acid may be monitored using Northern and/or Western analysis, both techniques being well known to persons having ordinary skill in the art.
- the generated transformed plants may be propagated by a variety of means, such as by clonal propagation or classical breeding techniques. For example, a first generation (or T1 ) transformed plant may be selfed and homozygous second-generation (or T2) transformants selected, and the T2 plants may then further be propagated through classical breeding techniques.
- the generated transformed organisms may take a variety of forms.
- they may be chimeras of transformed cells and non- transformed cells; clonal transformants (e.g., all cells transformed to contain the expression cassette); grafts of transformed and untransformed tissues (e.g., in plants, a transformed rootstock grafted to an untransformed scion).
- clonal transformants e.g., all cells transformed to contain the expression cassette
- grafts of transformed and untransformed tissues e.g., in plants, a transformed rootstock grafted to an untransformed scion.
- the invention relates to a method for producing a food or feed composition with increased lysine content comprising producing a transgenic plant with improved lysine content said method comprising
- sequences a1 , a2, b1 , and b2 are different sequences and are selected from SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, wherein
- b1 is SEQ ID NO: 4 or SEQ ID NO:
- a2 is SEQ ID NO: 2 or SEQ ID NO: 3, and
- a1 is SEQ I D NO: 2 or SEQ I D NO: 3
- b1 is SEQ ID NO: 3 or SEQ ID NO:
- step b) obtaining a progeny plant derived from the plant or plant cell of step a)
- the composition is a feed composition.
- Embodiments of the polynucleotide are as described elsewhere herein.
- Preferred plants, in particular of the genus Triticum are as described elsewhere herein.
- the food composition is flour or products using flour, such as bread.
- the method further comprises the step of selecting a lysine enriched part of said plant.
- this is seeds, for example Triticum grain.
- the method may further comprise screening plants for those that comprise the polynucleotide construct described herein and which have increased lysine content and selecting a plant that has an increased lysine content.
- further steps include measuring the lysine content in said plant progeny, part thereof or product derived, for example the food composition, thereform and comparing the lysine content to that of a control plant.
- the progeny plant is stably transformed and comprises the exogenous polynucleotide which is heritable maintained in the plant cell and the method may include steps to verify that the construct is stably integrated.
- the method may also comprise the additional step of collecting seeds from the selected progeny plant.
- the invention relates to a method for providing improved nutrition to a human or animal comprising feeding said human or animal on a diet comprising a food or feed composition obtained by a method for producing a transgenic plant with improved lysine content said method comprising
- sequences a1 , a2, b1 , and b2 are different sequences and are selected from SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, wherein
- a2 is SEQ ID NO: 2 or SEQ ID NO: 3, and
- a1 is SEQ I D NO: 2 or SEQ I D NO: 3
- b1 is SEQ ID NO: 3 or SEQ ID NO:
- step b) obtaining a progeny plant derived from the plant of step a) and
- Embodiments of the polynucleotide are as described elsewhere herein.
- Preferred plants, in particular of the genus Triticum are as described elsewhere herein.
- the food composition is flour or products using flour, such as bread.
- the method further comprises the step of selecting a lysine enriched part of said plant.
- the method may further comprise screening plants for those that comprise the polynucleotide construct above and which have an increased lysine content and selecting a plant that has an increased lysine content.
- further steps include measuring the lysine content in said plant progeny, part thereof or product derived thereform and comparing the lysine content to that of a control plant.
- the progeny plant is stably transformed and comprises the exogenous polynucleotide which is heritable as a fragment of DNA maintained in the plant cell and the method may include steps to verify that the construct is stably integrated.
- the method may also comprise the additional step of collecting seeds from the selected progeny plant.
- the invention in another aspect, relates to a method for treating a condition associated with lysine deficiency comprising administering to a patient or animal in need thereof an effective amount of a food composition of food supplement obtained by producing a plant or plant product with increased lysine content said method comprising
- sequences a1 , a2, b1 , and b2 are different sequences and are selected from SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, wherein
- a1 is SEQ ID NO: 1 or SEQ I D NO: 4
- b1 is SEQ I D NO: 4 or SEQ ID NO: 1
- a2 is SEQ ID NO: 2 or SEQ ID NO: 3
- a1 is SEQ ID NO: 2 or SEQ ID NO: 3
- b1 is SEQ I D NO: 3 or SEQ I D NO: 2
- a2 is SEQ ID NO: 1 or SEQ ID NO: 4
- the method can comprise the step of selecting patients with a condition that would benefit from said treatment.
- Conditions associated with lysine deficiency include appetite loss or deficiencies, such as delays, in growth and development, fatigue, mood changes, anxiety, cold sores and herpes simplex infections.
- EXAMPLE 1 Construction of the vectors pGhp- ⁇ / ⁇ / ⁇ / ⁇ and pDhp- ⁇ / ⁇ / ⁇ / ⁇ and ontaining transgenic wheat plants.
- PCR conditions for the two fragments were as follows: cDNA of T. aestivum cv Bobwhite synthesized from 50 ng of total RNA extracted from immature grains, 1 .5 mM of MgCI 2 , 0.2 mM of dNTPs, 0.2 ⁇ of each primer, 1x buffer, and 0.625 units of a mixture of polymerases in a 100 : 1 ratio of Tth (Thermus thermophilus) to Pfu (Pyrococcus furiosus) (BIOTOOLS, Madrid, Spain) in a final reaction of 25 ⁇ .
- Tth Thermus thermophilus
- Pfu Pyrococcus furiosus
- the conditions of the PCR cycles were as follows: an initial pass of 94°C 5 min, 35 cycles of 94°C 30 sec, 55°C 30 sec, and 72°C 30 sec; and a final extension of 72°C 4 min in a GeneAmp PCR system 9700 thermocycler (Applied Biosystems).
- the products of each PCR were purified using the GFX PCR DNA Purification Kit (Amersham Biosciences, Amersham, UK) and were sequenced by the firm Secugen SL.
- the ⁇ gliadin fragment was again amplified using an overlapping primer (overlapping Omega III R (SEQ ID NO: 12) together with the direct primer SEQ ID NO: 10), and the ⁇ / ⁇ gliadin fragment was again amplified using another overlapping primer, overlapping Alpha F (SEQ ID NO: 13), together with the reverse primer SEQ ID NO: 9) which added to each fragment 12 base pairs that were complementary with the other fragment.
- overlapping primer overlapping Omega III R (SEQ ID NO: 12) together with the direct primer SEQ ID NO: 10
- overlapping Alpha F SEQ ID NO: 13
- the PCR conditions were the same as described previously; the product of these reactions was separated in 1 % agarose gel and the band corresponding to each fragment was purified with the QUIAquick Gel Extraction Kit (QUIAGEN Inc., Valencia, CA).
- the final overlapping PCR was carried out using 10 ng of the ⁇ / ⁇ / ⁇ purified overlapping fragment, 10 ng of the purified ⁇ fragment, 1 .5 mM of MgCI 2 , 0.2 mM of dNTPs, 0.2 ⁇ of the primer alpha_hp-F, 0.2 ⁇ of the primer omega_lll-R, 1x buffer, and 0.625 units of a 100 : 1 mixture of Tth/Pfu polymerases in a final reaction of 50 ⁇ .
- the conditions of the PCR cycles were as follows: an initial pass of 94°C 2 min, 35 cycles of 94°C 30 sec, 57°C 30 sec, and 72°C 30 sec; and a final extension of 72°C 4 min in a GeneAmp PCR system 9700 thermocycler (Applied Biosystems).
- the product of these PCR was separated in 1 % agarose gel and the band showing the size corresponding to the ⁇ / ⁇ / ⁇ (361 bp) fragment was purified with the QUIAquick Gel Extraction Kit (QUIAGEN Inc., Valencia, CA) and cloned in the plasmid TOPO (Invitrogen, Carlsbad, CA).
- This plasmid comprises the sites aiiL1 and aiiL2 that allow transference through recombination of the gene of interest into any Gateway® vector that comprises the sites aiiR1 and aiiR2.
- the fragment attRsense_GUS_attRantisense (4.4 kb) of the vector pANDA was extracted by restriction combined with the enzymes Sacl and Kpnl and introduced into the vector puc18_Nost, giving rise to puc18_attR_GUS_Nost.
- This fragment contained the sites aiiR1 and aiiR2 with sense and antisense sequences separated by a linking segment of 1 kb (gus linker).
- This gus linker sequence was substituted for the Ubi intron fragment (1019 bp) previously cloned in our laboratory by restriction with the enzyme EcoRV, producing the plasmid puc18_attR_Ubi_Nost.
- the gliadin promoter (885 bp) was introduced by double restriction with the enzymes Sphl and Xhol, producing the plasmid puc18_Gli_attR_Ubi_Nost.
- the D-hordein gene promoter (836 bp) was also introduced by double restriction with the enzymes Sphl and Xhol, producing the vector puc18_D_attR_Ubi_Nost.
- the difference between the vectors pGhp- ⁇ / ⁇ / ⁇ / ⁇ and pDhp- ⁇ / ⁇ / ⁇ / ⁇ is that the former contains the promoter of wheat ⁇ gliadins and the latter contains the promoter of Barley D-hordein.
- the next step was the introduction of the fragment ⁇ / ⁇ / ⁇ into the plasmids puc18_Gli_attR_Ubi_Nost and puc18_D_attR_Ubi_Nost.
- the plasmid TOPO+ oo/a/ ⁇ contained the sites aiiL1 and aiiL2, while the plasmids puc18_Gli_attR_Ubi_NOSt and puc18_D_attR_Ubi_Nost contained the sites aiiR1 and aiiR2 with sense and antisense sequences separated by the intron Ubi.
- This made it possible to carry out an LR recombination reaction using the kit Gateway® LR Clonase TM Enzyme Mix (Invitrogen, Carlsbad, CA) and following the manufacturer's instructions.
- the result was the introduction of the fragment ⁇ / ⁇ / ⁇ / ⁇ having sense and antisense sequences separated by the intron Ubi into the structure of the plasmids puc18_Gli_attR_Ubi_NOSt and puc18_D_attR_Ubi_Nost.
- the resulting vectors were designated pGhp- ⁇ / ⁇ / ⁇ / ⁇ and pDhp- ⁇ / ⁇ / ⁇ / ⁇ (FIG. 2) and were introduced by transformation into competent E. coli cells (DH5a) for their subsequent multiplication.
- EXAMPLE 2 Obtaining transgenic wheat lines. Genetic transformation was carried out by biolistics using a system for accelerating particles with pressurized helium (PDS1000/HeTM. BIORAD, Hercules, CA). We used two genotypes of bread wheat (Triticum aestivum L.) cultivar Bobwhite (BW208 and BW2003) and one of hard wheat (Triticum turgidum ssp durum) cultivar Don Pedro to isolate the scutella from immature embryos.
- PDS1000/HeTM. BIORAD Hercules, CA.
- Isolation was carried out in a sterile environment using immature wheat grains collected 12-16 days after anthesis, previously sterilized by immersion for 3 min in a 70% ethanol solution, 10 min in a 20% sodium hypochlorite solution, and rinsing twice with sterile distilled H 2 0.
- gold particles 0.6 ⁇ in diameter and mixed in 1.5 pmoles/mg gold of the vector pGhp- ⁇ / ⁇ / ⁇ / ⁇ or the vector pDhp- ⁇ / ⁇ / ⁇ / ⁇ and 0.5 pmoles/mg of the vector pAHC25 (Christensen et al., 1996. Transgenic Research 5, 213-218).
- the conditions of each shot were as follows: 91.4 kPa (27 inHg) vacuum pressure, 7.584 MPa (1 100 PSI) shot pressure, 6 cm shot distance, and 60 ⁇ g of the mixture of gold and plasmids per shot.
- Cotransformation with the plasmid pAHC25 which contains the bar selection gene (resistance to phosphinothricin) and the uidA gene (synthesis of ⁇ - glucuronidase), allowed selection of the tissues transformed in media with 2 mg/l of phosphinothricin (PPT) and subsequent identification of transgenic tissues by means of the ⁇ - glucuronidase assay (GUS) in accordance with the protocol described by Jefferson (1987, Plant Mol Biol Rep 5:387-405). The media, the in vitro cultivation process, and regeneration of the plants were in accordance with Barro et al (Barro et al., 1998. Theoretical and Applied Genetics 97, 684-695).
- PPT phosphinothricin
- GUS ⁇ - glucuronidase assay
- the plants regenerated in in vitro cultivation were placed in the soil, and they were then subjected to the GUS assay per se and as described in the previous paragraph. From the plants that yielded a positive result in the GUS assay, DNA was extracted using DNAzol reagent (Invitrogen, Carlsbad, CA) following the manufacturer's instructions, and PCR was carried out to confirm the presence of the plasmids pGhp- ⁇ / ⁇ / ⁇ / ⁇ , pDhp- ⁇ / ⁇ / ⁇ / ⁇ , and pAHC25 in the genome of the adult plant.
- DNAzol reagent Invitrogen, Carlsbad, CA
- PCR conditions were as follows: 100 ng of DNA extracted from young leaves, 1 .5 mM MgCI 2 , 0.2 mM dNTPs, 0.2 ⁇ of each primer, 1x buffer, and 0.625 units of polymerase Tth (BIOTOOLS, Madrid, Spain).
- the primers used were prGNF (SEQ ID NO: 14) and overlapping Omega_lll_R (SEQ ID NO: 12) for the plasmid pGhp- ⁇ / ⁇ / ⁇ / ⁇ , prHorDF (SEQ ID NO: 15) and overlapping Omega_lll_R (SEQ ID NO: 12) for the plasmid pDhp- ⁇ / ⁇ / ⁇ / ⁇ and BAR_F (SEQ ID NO: 16) and BAR_R (SEQ ID NO: 17) for pAHC25 (Table 3).
- the conditions of the PCR cycles were as follows: an initial pass of 94°C 5 min, 35 cycles of 94°C 30 sec, 55°C 30 sec, and 72°C 2 sec; and a final extension of 72°C 7 min in a GeneAmp PCR system 9700 thermocycler (Applied Biosystems).
- the product of each PCR was separated by electrophoresis in 1 % agarose gel, and the positive lines were selected for subsequent analysis.
- EXAMPLE 3 Analysis of amino acid and gliadin content in transgenic lines
- transgenic low-toxic gluten lines were described or obtained as described in WO2010/089437 and contained the inverted repeat (IR) fragments ⁇ / ⁇ (vectors pGhp- ⁇ / ⁇ and pDhp- ⁇ / ⁇ ) designed to down regulate all the groups of gliadins by RNAi.
- IR inverted repeat
- White flour was obtained from each of the two independent repetitions of the transgenic and wild-type lines. Grains were hydrated to 16.5% humidity by addition of distilled water in two steps (24 h and 20 h before milling) with continuous shaking. Hydrated seeds (1 Kg) of each line were milled separately in two steps in a CD1 Chopin (Chopin Technologies, Villeneuve-la-Garenne Cedex, France) standardized test mill. In the first step white flour and wholemeal flour were obtained. The wholemeal flour was reloaded in a second step of milling, and the resultant white flour was blended with the obtained previously, resulting in a total yield of about 60%.
- assessors were provided with mineral water in order to cleanse their palate between tastings. Each assessor received a list of sensorial attributes and their definitions to guide them during the sample evaluation.
- the Pursuit XRs Ultra 2.8 C18 100x2.0 mm column (Agilent) was used as stationary phase, and the flow was 200 ⁇ min "1 .
- the detection was performed by MS with the ionization mode ESI (positive and negative).
- the amount of amino acid is expressed as percentage of the total sample weight. The results are shown in Table 4.
- Methionine ⁇ 0.05 ⁇ 0.05 ⁇ 0.05 ⁇ 0.05 ⁇ 0.05 ⁇ 0.05 ⁇ 0.05 ⁇ 0.05 ⁇ 0.05 ⁇ 0.05 ⁇ 0.05 ⁇ 0.05 ⁇ 0.05 ⁇ 0.05
- Tryptophan ⁇ 0.05 ⁇ 0.05 ⁇ 0.05 ⁇ 0.05 ⁇ 0.05 ⁇ 0.05 ⁇ 0.05 ⁇ 0.05 ⁇ 0.05 ⁇ 0.05 ⁇ 0.05 ⁇ 0.05 ⁇ 0.05 ⁇ 0.05
- Non gluten proteins (% DW) 4,3433 7,3852 * 7,8092 *
- alpha, omega and gamma gliadins are downregulated in the transgenic lines.
- Non-gluten proteins are upregulated, i.e. globulins and albumins, are upregulated. This fraction contains proteins very rich in lysine.
- N. M. Houmard et al. High-lysine corn generated by endosperm-specific suppression of lysine catabolism using RNAi. Plant Biotechnology Journal 5, 605 (2007-Sep, 2007).
- X. R. Wu et al. Altered expression of plant lysyl tRNA synthetase promotes tRNA misacylation and translational recoding of lysine. Plant J 50, 627 (May, 2007).
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
Abstract
Description
Claims
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14732858.7A EP3011036B1 (en) | 2013-06-18 | 2014-06-18 | Transgenic plants |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13382228 | 2013-06-18 | ||
| PCT/EP2014/062870 WO2014202688A1 (en) | 2013-06-18 | 2014-06-18 | Transgenic plants |
| EP14732858.7A EP3011036B1 (en) | 2013-06-18 | 2014-06-18 | Transgenic plants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3011036A1 true EP3011036A1 (en) | 2016-04-27 |
| EP3011036B1 EP3011036B1 (en) | 2021-11-10 |
Family
ID=48672544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP14732858.7A Active EP3011036B1 (en) | 2013-06-18 | 2014-06-18 | Transgenic plants |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9976156B2 (en) |
| EP (1) | EP3011036B1 (en) |
| ES (1) | ES2905768T3 (en) |
| WO (1) | WO2014202688A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016202805A2 (en) * | 2015-06-15 | 2016-12-22 | Consejo Superior De Investigaciones Científicas (Csic) | Targeting of prolamin by rnai in bread wheat |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2343618B1 (en) * | 2009-02-03 | 2011-06-20 | Consejo Superior De Investigaciones Cientificas (Csic) | POLINUCLEOTIDE THAT INCLUDES SEQUENCES OF WHEAT GLIADINES AND ITS USE FOR SILENCING BY RNAI. |
-
2014
- 2014-06-18 ES ES14732858T patent/ES2905768T3/en active Active
- 2014-06-18 US US14/899,698 patent/US9976156B2/en active Active
- 2014-06-18 WO PCT/EP2014/062870 patent/WO2014202688A1/en not_active Ceased
- 2014-06-18 EP EP14732858.7A patent/EP3011036B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014202688A1 (en) | 2014-12-24 |
| US9976156B2 (en) | 2018-05-22 |
| ES2905768T3 (en) | 2022-04-12 |
| US20160222400A1 (en) | 2016-08-04 |
| EP3011036B1 (en) | 2021-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108135235B (en) | Potato cultivar X17 | |
| CN102307999B (en) | Polynucleotides comprising wheat prolamin sequences and their use in RNAi silencing | |
| CN107205354A (en) | haploid inducer | |
| JP2010279296A (en) | Gene for increasing protein content of seed and method for using the same | |
| MX2011001581A (en) | Plants with altered root architecture, related constructs and methods involving genes encoding protein phophatase 2c (pp2c) polypeptides and homologs thereof. | |
| CA3022345A1 (en) | Construct and vector for intragenic plant transformation | |
| WO2014150879A1 (en) | Compositions and methods for increasing plant seed number and/or yield | |
| US11879128B2 (en) | Targeting of gluten by genome editing | |
| US20140215653A1 (en) | Identification and use of early embryo and/or early endosperm specific promoters for gene expression in maize | |
| EP3011036B1 (en) | Transgenic plants | |
| WO2019027871A1 (en) | Peanut with reduced allergen levels | |
| WO2016202805A2 (en) | Targeting of prolamin by rnai in bread wheat | |
| Barro Losada | Transgenic plants | |
| US20110035837A1 (en) | Plants having altered agronomic characteristics under nitrogen limiting conditions and related constructs and methods involving genes encoding lnt3 polypeptides | |
| JP4880338B2 (en) | Transgenic rice expressing glutenin subunits of wheat | |
| JP5850078B2 (en) | Gene for reducing protein content of seed and method of using the same | |
| EP4144849A1 (en) | Method for obtaining wheat with increased resistance to powdery mildew | |
| WO2022238443A1 (en) | Reduced gliadin wheat event t258 | |
| JP5850079B2 (en) | Gene for reducing protein content of seed and method of using the same | |
| JP5845306B2 (en) | Gene for increasing protein content of seed and method for using the same | |
| JP2014042516A (en) | Transformed plant having high phytic acid synthesizing ability and high phosphorous absorbing ability |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20160113 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20161025 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20201120 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
| GRAL | Information related to payment of fee for publishing/printing deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR3 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| INTC | Intention to grant announced (deleted) | ||
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| INTG | Intention to grant announced |
Effective date: 20210924 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1446124 Country of ref document: AT Kind code of ref document: T Effective date: 20211115 Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602014081155 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20211110 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2905768 Country of ref document: ES Kind code of ref document: T3 Effective date: 20220412 |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1446124 Country of ref document: AT Kind code of ref document: T Effective date: 20211110 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211110 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211110 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211110 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220210 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211110 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220310 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211110 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220310 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211110 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220210 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211110 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211110 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211110 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220211 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211110 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211110 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211110 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211110 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211110 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211110 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602014081155 Country of ref document: DE |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed |
Effective date: 20220811 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211110 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211110 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211110 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20220630 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220618 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220630 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220618 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220630 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220630 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20140618 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211110 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211110 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211110 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20250618 Year of fee payment: 12 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20250625 Year of fee payment: 12 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20250620 Year of fee payment: 12 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20250718 Year of fee payment: 12 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20250630 Year of fee payment: 12 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211110 |